Core Insights - Hutchison China MediTech Limited (Chi-Med) will present updated data on several of its self-developed compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China [1] Group 1: Upcoming Conferences - The 2025 WCLC will take place from September 6 to 9 in Barcelona, Spain [1] - The 2025 CSCO Annual Meeting will be held from September 10 to 14 in Jinan, China [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and Chi-Med, with commercialization by AstraZeneca [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be presented for the first time at the CSCO Annual Meeting [1]